alexa Hairy cell leukemia (HCL) | Russia | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

  • 7th World Hematologists Congress May 08-09, 2017 Barcelona, Spain
    May 08-09, 2017 Barcelona, Spain
  • 8th International Conference on Blood Cancer & Treatment June 26-27, 2017 London, UK
    June 26-27, 2017 London, UK
  • International Conference on Hematology and Oncology June 29-July 01, 2017 Bangkok, Thailand
    June 29-July 01, 2017 Bangkok, Thailand
  • 9th International Conference on Hematology November 02-03, 2017 Las Vegas, USA
    November 02-03, 2017 Las Vegas, USA
  • 11th International Conference on Leukemia and Hematologic Oncology December 04-05, 2017 Madrid, Spain
    December 04-05, 2017 Madrid, Spain
Read more

Recommended Journals

Relevant Topics

Hairy Cell Leukemia (HCL)

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Hairy cell leukemia (HCL)

    Hairy cell leukemia is a rare, slow-growing cancer of the blood in which your bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. These excess B cells are abnormal and look "hairy" under a microscope.

  • Hairy cell leukemia (HCL)

    Common symptoms of HCL includes persistently feeling tired, weakness, weight loss for no reason, shortness of breath, excessive sweating (most often at night), swollen lymph nodes, frequent infections and fevers, small red spots on the skin. The main treatment for hairy cell leukemia is chemotherapy, purine analog drugs either cladribine (2-CdA) or pentostatin, monoclonal antibody rituximab, surgery or interferon alpha.

  • Hairy cell leukemia (HCL)

    Hairy cell leukemia is relatively uncommon and accounts for 2% of all leukemia cases, which is about 600-800 new patients diagnosed each year. Complete and partial remissions were achieved in 56% and 28% of the patients, respectively. Mortality rate was reported in 3% of the diseased patients for past 3 years. 

Expert PPTs

Speaker PPTs

 

High Impact List of Articles

Conference Proceedings